# TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC

> **NCT07498595** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University General Hospital** · enrollment: 50 (estimated)

## Conditions studied

- EGFR-TKI-resistant Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** TILs infusion

## Key facts

- **NCT ID:** NCT07498595
- **Lead sponsor:** Tianjin Medical University General Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2028-03-31
- **Final completion:** 2030-03-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07498595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07498595, "TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07498595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*